金属硫蛋白与单抗SZ51重组蛋白在大肠杆菌菌株BL21(DE3)pLysS中表达的研究

从基因工程水平构建了小鼠金属硫蛋白与抗人活化血小板单抗ＳＺ５１单链抗体的重组基因产物,并在大肠杆菌菌株ＢＬ２１（ＤＥ３）ｐＬｙｓＳ中成功地进行了表达．该重组蛋白以包涵体形式存在于菌体蛋白中,分子量为３８ｋＤ,ＥＬＩＳＡ实验证明该重组蛋白既具有血栓部位活化血小板的单抗活性,又具有小鼠ＭＴ单抗的活性     

具有谷胱甘肽过氧化物酶活性的含硒单链抗体酶制备

 利用RT PCR从分泌有谷胱甘肽结合部位的单克隆抗体杂交瘤细胞株 2F3中 ,扩增出单抗重链可变区和轻链可变区基因 .经DNA测序后 ,用Linker(Gly4 Ser1) 3 构建成单链抗体 (scFv)表达载体pTMF scFv ,将重组质粒pTMF scFv转化到大肠杆菌BL2 1(DE3) ,实现了单链抗体的高效表达 .表达的单链抗体占菌体总蛋白 2 5%～ 30 % .该重组蛋白以包涵体形式存在 ,分子量为 30kD .经过金属螯合亲和层析纯化、复性和凝胶过滤纯化 ,得到电泳均一的单链抗体 .再经化学诱变 ,得到含硒单链抗体酶 ,其谷胱甘肽过氧化物酶活性为 330 0U μmol.采用荧光滴定法测定了单链抗体对谷胱甘肽的结合常数     

抗金黄色葡萄球菌单链抗体(scFv)的原核表达及蛋白纯化

旨在将来源于鸡的金黄色葡萄球菌单链抗体(scFv)进行原核诱导表达,获得有抗体活性的目的蛋白。构建含有目的抗体基因的重组质粒,将此质粒进行原核诱导表达并鉴定所获得蛋白的生物活性。结果显示,(1)成功构建了含有金黄色葡萄球菌单链抗体(scFv)的重组质粒p Cold I-scFv,质粒成功转化到大肠杆菌表达菌株中;(2)经过诱导表达后,目的蛋白主要以包涵体的形式存在于沉淀中;(3)使用4 mol/L尿素成功地将包涵体变性溶出;(4)通过柱层析法及透析法获得了纯化及复性效果较好的目的蛋白;(5)间接ELISA鉴定证实所获蛋白具有金黄色葡糖球菌抗体活性。通过质粒构建及原核诱导表达、包涵体溶出和复性等步骤,最终获得了有金黄色葡萄球菌抗体活性的目的蛋白。     

柑桔溃疡病菌重组单链抗体的高效表达及活性检测

运用PCR方法扩增利用核糖体展示技术筛选的抗柑桔溃疡病菌(Xanthomonas axonopodis pv.citri,XAC)的单链抗体(ScFv95)基因片段,将单链抗体基因重组到原核表达载体pET30a( )中,构建单链抗体高效表达载体pET30a( )-XAC-ScFv。再将pET30a( )-XAC-ScFv质粒转化进大肠杆菌BL21(DE3)后诱导表达,并对表达产物进行纯化、复性及活性检测。获得了抗XAC单链抗体的高效表达蛋白,以包涵体形式存在的表达蛋白大小约32kDa。包涵体蛋白经过变性、纯化和复性后,初步获得有功能的单链抗体。同时用Biacore分析XAC-ScFv-95与XAC LPS作用,结果表明复性后的XAC-ScFv-95具有较高的亲和力,从而为柑桔溃疡病菌XAC的免疫诊断和防治研究提供了新的工具和途径。     

人血小板衍生生长因子BB亚型包涵体复性与纯化

目的:优化人血小板衍生生长因子BB亚型(PGDF-BB)包涵体复性方法与纯化条件,获得具有较好生物活性的重组PGDF-BB蛋白。方法:对PGDF-BB包涵体以梯度尿素进行变性,选择最佳包涵体变性浓度;比较不同复性条件下的复性率,稳定PGDF-BB包涵体复性方法;参照该蛋白的理化性质,选择适合PGDF-BB重组蛋白的纯化方法。结果:原核系统内实现了PGDF-BB的高表达;通过优化包涵体复性方法,重组蛋白的包涵体复性率可达40%以上;经过多个纯化方法相结合,PGDF-BB的纯度达到95%。结论:通过实验条件的优化,提高了PGDF-BB包涵体复性率,获得高纯度、高生物活性的重组PGDF-BB蛋白。     

牙鲆甲状腺激素受体TRαA的原核表达和多克隆抗体的制备及应用

为研究牙鲆甲状腺激素受体TRαA在牙鲆变态发育过程中的调控作用,将TRαA基因克隆插入融合表达栽体pET30a,并在大肠杆菌Escherichia coli DE3(BL21)中进行诱导表达.表达菌株经1 mmol/L异丙基-β-D-硫代半乳糖苷(IPTG)诱导4 h后,重组蛋白TRaA表达并形成包涵体.SDS-PAGE和Western blotting检测鉴定表达产物.包涵体经变性后在His-Bind树脂进行亲和层析纯化,柱上复性法对重组蛋白复性,获得纯度较高的目的蛋白,蛋白复性的效果良好.用纯化后的目的蛋白免疫新西兰家兔制备多克隆抗体.Dot blotting检测抗体效价达1:200 000,检测证明抗体特异性良好.此外,通过染色质免疫沉淀技术鉴定了在活体细胞中多克隆抗体与TRαA的特异性结合.表明了甲状腺激素通过其受体在体内参与碱性磷酸酶(ALP)基因的转录调控.     

抗SARS 人源单链抗体H12的表达及复性

从SARS免疫抗体库获得的一株抗SARS-CoV人源单链抗体H12,亟待鉴定.为了快速制备大量具有生物活性的单链抗体H12,构建了pET28a-H12原核高表达载体,表达量占菌体总蛋白质30%以上.采用稀释复性和分子筛柱复性两种方法对包涵体蛋白进行复性与纯化,结果显示两种方法都能使得单链抗体复性.与稀释复性法相比,柱复性效果更好,其抗原结合活性是稀释复性法的1.51倍.柱复性后的单链抗体亲和力测定的解离常数Kd为73.5nmol/mL.为进一步研究单链抗体H12的功能奠定了基础.     

重组抗人活化血小板单链抗体-尿激酶原导向溶栓剂的基因构建及表达

为了获得特异性高的导向溶栓药物,应用PCR技术,得到抗人活化血小板单抗(SZ-51)的Fab′基因片段。再用酶切方法,将Fab′中CH1基因片段替换成合成的连接分子(linker)基因,构建成单链抗体基因,并插入到人尿激酶原分泌肽基因及低分子量单链尿激酶(scu-PA-32k)之间,最终构建成重组抗人活化血小板单链抗体-尿激酶原融合蛋白基因。此融合蛋白基因在昆虫细胞中得到表达。纯化的表达产物SDS-PAGE鉴定,其分子量约为60kD,与预期值相符。其比活为9000IU/mg蛋白。ELISA法初步证明此重组的融合蛋白具有与活化血小板抗原结合特异性。     

牙鲆甲状腺激素受体TRaA的原核表达和多克隆抗体的制备及应用

为研究牙鲆甲状腺激素受体TRαA在牙鲆变态发育过程中的调控作用,将TRαA基因克隆插入融合表达载体pET30a,并在大肠杆菌Escherichia coli DE3(BL21)中进行诱导表达。表达菌株经1mmol/L异丙基-β-D-硫代半乳糖苷(IPTG)诱导4h后,重组蛋白TRαA表达并形成包涵体。SDS-PAGE和Western blotting检测鉴定表达产物。包涵体经变性后在His-Bind树脂进行亲和层析纯化,柱上复性法对重组蛋白复性,获得纯度较高的目的蛋白,蛋白复性的效果良好。用纯化后的目的蛋白免疫新西兰家兔制备多克隆抗体。Dotblotting检测抗体效价达1:200000,检测证明抗体特异性良好。此外,通过染色质免疫沉淀技术鉴定了在活体细胞中多克隆抗体与TRαA的特异性结合,表明了甲状腺激素通过其受体在体内参与碱性磷酸酶(ALP)基因的转录调控。     

人呼吸道合胞病毒截短F1重组蛋白包涵体的制备、纯化和复性

目的将前期在大肠埃希杆菌中获得表达的A型人呼吸道合胞病毒兰州分离株截短的F1重组蛋白进行纯化和复性,为后期动物免疫制备抗原。方法 37℃诱导重组菌体p ET-42b-F1J/Rossata,诱导完毕后离心收集菌体,高压破碎菌体并收集包涵体后用不同浓度的Triton X-100(细胞裂解液)洗涤包涵体3次。洗涤的包涵体用8 mol/L尿素进行溶解并用镍离子亲和层析方法进行初步纯化,用阳离子交换层析方法对初步纯化蛋白进行最终的纯化。亲和层析纯化蛋白用3种不同的复性液进行了稀释复性。结果 37℃诱导5 000 m L重组菌p ET-42b-F1J/Rossata共收获37 g湿菌体,经过不同浓度Triton X-100洗涤包涵体后纯度可达75%。包涵体用8 mol/L尿素溶解后经镍离子亲和层析纯化纯度约为40%,再用阳离子交换层析介质SP HP进一步纯化样品后纯度可达90%。纯化蛋白以3种不同的复性液都能得到复性,其中复性液3的复性效果相对较好。结论实验中探索了人呼吸道合胞病毒截短F1重组蛋白包涵体的纯化方法及步骤,为后期的蛋白制备及动物免疫奠定了基础。     

金属硫蛋白导向血栓单抗化学偶联体的制备及性质研究

金属硫蛋白（ｍｅｔａｌｏｔｈｉｏｎｅｉｎ,简称ＭＴ）是一类低分子量、富含半胱氨酸的蛋白质,由于１个ＭＴ分子可结合７个金属离子,因此ＭＴ分子具有很强的金属结合特性［１,２］．本文一方面利用ＭＴ分子的高金属结合性能,另一方面利用苏州医学院血液研究所研制成...     

Improving the refolding of NTA protein by urea gradient and arginine gradient size-exclusion chromatography

Inclusion body refolding processes play a major role in the production of recombinant proteins. Improvement of the size-exclusion chromatography refolding process was achieved by combining a decreasing urea gradient with an increasing arginine gradient (two gradients) for the refolding of NTA protein (a new thrombolytic agent) in this paper. Different refolding methods and different operating conditions in two gradients gel filtration process were investigated with regard to increasing the NTA protein activity recovery and inhibition of aggregation. The refolding of denatured NTA protein showed this method could significantly increase the activity recovery of protein at high protein concentration. The activity recovery of 37% was obtained from the initial NTA protein concentration up to 20 mg/ml. The conclusions presented in this study could also be applied to the refolding of lysozyme.     

An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin

Human recombinant prethrombin-2 was produced in Escherichia coli. The expressed prethrombin-2 formed intracellular inclusion bodies from which the protein was refolded by a simple one-step dilution process in buffer consisting of 50 mM Tris-HCl, containing 20 mM CaCl(2), 500 mM NaCl, 1 mM EDTA, 600 mM arginine, 1 mM cysteine, 0.1 mM cystine, 10% (v/v) glycerol, and 0.2% (w/v) Brij-58 at pH 8.5. After refolding, prethrombin-2 was purified by hirudin-based COOH-terminal peptide affinity chromatography, and then activated with Echis carinatus snake venom prothrombin activator (ecarin). The activated protein, alpha-thrombin, was then tested for several activities including activity toward chromogenic substrate, release of fibrinopeptide A from fibrinogen, activation of protein C, and thrombin-activatable fibrinolysis inhibitor, reactivity with antithrombin, clotting activity, and platelet aggregation. The kinetic data showed no differences in activity between our recombinant alpha-thrombin and plasma-derived alpha-thrombin. The yield of refolded recombinant human prethrombin-2 was about 4-7% of the starting amount of solubilized protein. In addition, the final yield of purified refolded protein was 0.5-1%, and about 1 mg of recombinant prethrombin-2 could be isolated from 1 liter of E. coli cell culture.     

Imaging thrombus with radiolabelled monoclonal antibody to platelets.

Indium-111-hydroxyquinoline labelled platelets, though useful in the detection of thrombus, have not gained widespread use owing to the time and technical skill required for their preparation. A study was therefore conducted evaluating a new method of imaging thrombus with platelets radiolabelled with a 111In labelled monoclonal antibody, P256, directed to the platelet surface glycoprotein complex IIb/IIIa. When the number of receptors occupied by P256 was less than 3% of the total available on the platelet surface platelet function, as assessed by platelet aggregometry, was undisturbed. P256 was radiolabelled with 111In using diethylenetriaminepenta-acetic acid, which achieved a specific activity of 185 MBq (5 mCi)/mg. No impairment of immunoreactivity was detected at this specific activity. Platelets were labelled with radiolabelled monoclonal antibody in vitro in two patients at a receptor occupancy of 6% and in vivo--that is, by direct intravenous injection of P256--in six patients at a receptor occupancy of 1%. In vivo recovery and biodistribution kinetics suggested that after in vitro labelling platelets were minimally activated. The 111In kinetics recorded after intravenous P256 suggested rapid and efficient radiolabelling of platelets and gave no indication of platelet activation. Of the six patients who received intravenous P256, three had documented thrombus, two of whom gave positive results on P256 platelet scintigraphy. The third subject had chronic deep venous thrombosis and was scintigraphically negative. Imaging thrombus using a radiolabelled monoclonal antibody directed to platelets appears to offer great potential as a simple, non-invasive approach to the diagnosis of thrombosis.     

胆汁三烯结合蛋白在大肠杆菌中的表达、复性与纯化

目的：合成胆汁三烯结合蛋白（BBP）基因并在大肠杆菌中表达,获得重组BBP纯化制品。方法：根据天然BBP的基因序列和大肠杆菌偏好密码子设计并合成BBP基因的引物,PCR扩增优化的BBP基因序列,克隆至载体pEasy-T3;测序正确后,将该序列克隆至表达载体pET-32a上,构建表达质粒,转化至大肠杆菌BL21（DE3）pLysS,在IPTG诱导下表达融合蛋白;采用Ni柱纯化融合蛋白。结果：PCR扩增获得了优化后的BBP基因序列,构建了表达载体pET-32a-BBP;SDS-PAGE分析表明表达的融合蛋白相对分子质量为20×10^3,以包涵体形式存在,占全菌蛋白的40%以上;变性、复性后经Ni2＋柱纯化,获得纯度达98%以上的重组蛋白。结论：优化并合成了BBP全基因序列,获得了高纯度重组融合蛋白,为进一步鉴定其生物活性及筛选小分子的研究奠定了基础。     

An Efficient System for Production of Recombinant Urokinase-Type Plasminogen Activator

A system was developed to produce recombinant urokinase-type plasminogen activator inEscherichia coli.The urokinase-type plasminogen activator was produced with a 6× His-tag at the C-terminus which was shown to have the same activity, after refolding, as the wild-type protein. Purification of the recombinant protein to homogeneity (95%) was possible by one-step affinity chromatography under denaturing conditions. As a result, proteolysis by bacterial proteases during purification was avoided. A higher refolding efficiency (40%) and a higher total recovery yield (25%) of the recombinant protein were obtained by this method.     

huGM-CSF(9-127)-IL-6(29-184)融合蛋白的复性及纯化研究

利用Q Sepharose H.P.离子交换柱层析在8mol/L尿素变性条件下对huGM-CSF(9-127)-IL-6(29-184）融合蛋白进行初步纯化,然后再利用Sephacryl S-200分子筛柱层析复性及纯化后获得目的蛋白,其纯度达到95％以上。该纯化方案成功地解决了稀释复性或透析复性产物在进行Q Sepharose H.P.离子交换柱层析时目的蛋白不稳定而沉积于柱上的问题,获得了较好的复性效果,复性率达到80％以上。使用该纯化方案,1天内便可基本完成重组蛋白的复性及纯化过程,而且也便于扩大。     

HIV-1 CN54 Pol P51抗原高效表达、纯化、复性及在抗体检测中的应用

为获得可溶性高纯度HIV-1中国株CN54PolP51抗原,将携带CN54polp51基因的重组质粒pTHioHisA51转化大肠杆菌BL21codonplus-RIL,用IPTG进行诱导表达。用Chelating SepharoseFF-Ni亲和层析柱及DEAE Sepharose Fast Flow阴离子交换层析柱纯化目的蛋白,采用透析复性法得到可溶性抗原,Western blotting检测目的蛋白。用纯化的P51抗原蛋白标记辣根过氧化物酶及包被酶标板进行双抗原夹心法ELISA检测。结果显示P51以包涵体的形式表达,表达量占菌体总蛋白的50%,经两步层析和透析复性,目的蛋白纯度大于95%。Western blotting和双抗原夹心法ELISA检测均显示了良好的灵敏度和特异性。本研究可以为HIV-1疫苗研究和开发检测试剂提供支持。